Nguyen Hong-My, Saha Dipongkor
Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, School of Pharmacy, Abilene, TX, 79601, USA.
Oncolytic Virother. 2021 Feb 24;10:1-27. doi: 10.2147/OV.S268426. eCollection 2021.
Glioblastoma (GBM) is a lethal primary malignant brain tumor with no current effective treatments. The recent emergence of immuno-virotherapy and FDA approval of T-VEC have generated a great expectation towards oncolytic herpes simplex viruses (oHSVs) as a promising treatment option for GBM. Since the generation and testing of the first genetically engineered oHSV in glioma in the early 1990s, oHSV-based therapies have shown a long way of great progress in terms of anti-GBM efficacy and safety, both preclinically and clinically. Here, we revisit the literature to understand the recent advancement of oHSV in the treatment of GBM. In addition, we discuss current obstacles to oHSV-based therapies and possible strategies to overcome these pitfalls.
胶质母细胞瘤（GBM）是一种致命的原发性恶性脑肿瘤，目前尚无有效的治疗方法。免疫病毒疗法的最新出现以及FDA对T-VEC的批准，使人们对溶瘤单纯疱疹病毒（oHSV）作为GBM的一种有前景的治疗选择寄予厚望。自20世纪90年代初在胶质瘤中首次产生和测试基因工程oHSV以来，基于oHSV的疗法在临床前和临床的抗GBM疗效和安全性方面都取得了长足的进展。在此，我们回顾文献以了解oHSV在GBM治疗中的最新进展。此外，我们还讨论了基于oHSV疗法目前面临的障碍以及克服这些缺陷的可能策略。
